https://scholars.lib.ntu.edu.tw/handle/123456789/535221
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | YU-CHUNG CHUANG | en_US |
dc.contributor.author | PAO-YU CHEN | en_US |
dc.contributor.author | Lin C.-Y. | en_US |
dc.contributor.author | YEE-CHUN CHEN | en_US |
dc.contributor.author | JANN-TAY WANG | en_US |
dc.contributor.author | SHAN-CHWEN CHANG | en_US |
dc.creator | Yu-Chung Chuang;Chen P.-Y.;Lin C.-Y.;Chen Y.-C.;Wang J.-T.;Chang S.-C. | - |
dc.date.accessioned | 2020-12-29T03:48:08Z | - |
dc.date.available | 2020-12-29T03:48:08Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 2045-2322 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85041139175&doi=10.1038%2fs41598-018-19986-8&partnerID=40&md5=97a4cbdab5bdead9c1002e030467f63e | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/535221 | - |
dc.description.abstract | There is limited clinical evidence to support the combination of daptomycin and beta-lactam antibiotics (DAP + BLA) for treatment of vancomycin-resistant enterococci (VRE) bloodstream infections (BSI). We conducted a prospective observational cohort study of VRE-BSI during 2010-2015. The primary endpoint was mortality at the end of treatment. We included 114 patients who received DAP for VRE-BSI. Of these 87 (76.3%) received DAP + BLA. There were no significant differences in mortality between the DAP and DAP + BLA groups on univariable analysis (10/27 vs. 34/87, P = 0.85). A subgroup analysis of patients with enterococcal DAP minimum inhibitory concentrations (MICs) ?2 mg/L, revealed that those treated with DAP + BLA had a lower mortality (adjusted hazard ratio [aHR], 0.23; 95% confidence interval [CI], 0.06-0.93; P = 0.04) after adjustment for other significant predictors of mortality, including the DAP dose. In addition, patients receiving high-dose (?9 mg/kg) DAP + BLA independently had a better survival than those receiving low-dose DAP alone (aHR = 5.16), low-dose DAP + BLA (aHR = 5.39), and high-dose DAP alone (aHR = 19.01) (P < 0.05 for all comparisons). For patients with VRE-BSIs, the DAP MIC of the isolate and the DAP dose influence the effect of DAP + BLA on outcome. A high-dose DAP + BLA might improve survival. These findings support the use of high-dose DAP + BLA for treatment of VRE-BSI. ? 2018 The Author(s). | - |
dc.publisher | Nature Publishing Group | - |
dc.relation.ispartof | Scientific Reports | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | antiinfective agent; beta lactam; daptomycin; aged; bacteremia; combination drug therapy; Enterococcus faecium; female; Gram positive infection; human; isolation and purification; male; microbiology; middle aged; procedures; retrospective study; survival analysis; treatment outcome; vancomycin resistant Enterococcus; very elderly; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactams; Daptomycin; Drug Therapy, Combination; Enterococcus faecium; Female; Gram-Positive Bacterial Infections; Humans; Male; Middle Aged; Retrospective Studies; Survival Analysis; Treatment Outcome; Vancomycin-Resistant Enterococci | - |
dc.title | A retrospective clinical comparison of daptomycin vs daptomycin and a beta-lactam antibiotic for treating vancomycin-resistant Enterococcus faecium bloodstream infections | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1038/s41598-018-19986-8 | - |
dc.identifier.pmid | 29374204 | - |
dc.relation.pages | 1632 | - |
dc.relation.journalvolume | 8 | - |
dc.relation.journalissue | 1 | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Center for Infection Control | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Center for Infection Control | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Office of the Vice President | - |
crisitem.author.dept | Clinical Pharmacy | - |
crisitem.author.dept | Medical Education and Bioethics | - |
crisitem.author.orcid | 0000-0003-3094-8276 | - |
crisitem.author.orcid | 0000-0001-9499-1842 | - |
crisitem.author.orcid | 0000-0002-1816-9010 | - |
crisitem.author.orcid | 0000-0002-0924-3469 | - |
crisitem.author.orcid | 0000-0001-6505-4139 | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | Administrative Unit | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。